A Phase III, Open-Label, Multicentre, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
This Phase III, open-label, randomized, multicentre study is to evaluate the efficacy and
safety of adjuvant treatment with atezolizumab compared with observation in participants
with muscle-invasive urothelial carcinoma (UC) who are at high risk for recurrence following
resection. Eligible participants will be randomized by a 1:1 ratio into atezolizumab group
or control group.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society